Drug Profile
RI 273
Alternative Names: mAb 2256; RI-273Latest Information Update: 26 Apr 2005
Price :
$50
*
At a glance
- Originator Rinat Neuroscience
- Class Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis; Pain
Most Recent Events
- 26 Apr 2005 Discontinued - Preclinical for Amyotrophic lateral sclerosis in USA (unspecified route)
- 26 Apr 2005 Discontinued - Preclinical for Pain in USA (unspecified route)
- 21 Aug 2003 Preclinical trials in Amyotrophic lateral sclerosis in USA (unspecified route)